Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | EZH2 | Q15910 | 6/20 | 0.36 |
| ▸ | EED | O75530 | 1/20 | 0.33 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.33 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.33 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.31 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.31 |
| ▸ | PIM1 | P11309 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | CLK2 | P49760 | 2/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20499757 | 0.84 | EZH2 (0.43) | KDM4EALDH1A1HPGDPOLBTSHR | |
| SCHEMBL15815035 | 0.81 | KDM4E (0.36) | KDM4EALDH1A1HPGDPOLBTSHR | |
| SCHEMBL15814409 | 0.79 | EED (0.36) | KDM4EALDH1A1HPGDPOLBTSHR | |
| SCHEMBL15815050 | 0.78 | EED (0.35) | KDM4EALDH1A1HPGDPOLBTSHR | |
| SCHEMBL16821944 | 0.74 | EZH2 (0.31) | KDM4EALDH1A1HPGDPOLBTSHR | |
| SCHEMBL15830727 | 0.74 | P2RX3 (0.37) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL20499628 | 0.71 | EZH2 (0.45) | KDM4EALDH1A1HPGDPOLBTSHR | |
| SCHEMBL15813989 | 0.71 | EZH2 (0.69) | EZH2 | |
| SCHEMBL15814278 | 0.69 | NCOA1 (0.43) | KDM4EALDH1A1HPGDNCOA1NCOA3 | |
| SCHEMBL15814855 | 0.68 | PARP10 (0.35) | NCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3339303-B9 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3339303-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10246433-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3339303-A1 | ARYL AND HETEROARYL FUSED LACTAMS | Pfizer Inc (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2935238-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20170233368-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233368-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20150175572-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175572-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-9040515-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040515-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140179667-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179667-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014097041-A1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER INC. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179667-A1 | ARYL AND HETEROARYL FUSED LACTAMS | CCNY, MLX, NFXL1 | KDM4E 988/4885ALDH1A1 2245/4885HPGD 3759/4885 |
| US-20170233368-A1 | ARYL AND HETEROARYL FUSED LACTAMS | CCNY, MLX, NFXL1 | KDM4E 988/4885ALDH1A1 2245/4885HPGD 3759/4885 |
| US-20150175572-A1 | ARYL AND HETEROARYL FUSED LACTAMS | CCNY, MLX, NFXL1 | KDM4E 988/4885ALDH1A1 2245/4885HPGD 3759/4885 |
| US-10246433-B2 | Aryl and heteroaryl fused lactams | CCNY, MLX, NFXL1 | KDM4E 988/4885ALDH1A1 2245/4885HPGD 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.